Post hoc biomarker analysis of phase 3 BLISS-LN (446 adults with lupus nephritis; about 50–60% with week-104 data): belimumab vs placebo reduced CD19+ and naïve B cells; high baseline IgA, anti-C1q and naïve B cells predicted kidney response.
Secondary analysisn = 446
Rovin et al. Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis